The Foresight CLARITY test offers greater prognostic accuracy than PET/CT scans in large B-cell lymphoma by detecting ctDNA-MRD negativity, indicating better patient outcomes. ctDNA-MRD testing showed ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...